Prognostic Significance of Molecular Profile in Non-metastatic Invasive Breast Cancer: A Multicentre Study from India

Abstract

To give the molecular profiling and its association with DFS among women with early breast cancer (EBC) and locally advanced breast cancer (LABC). This cohort study used secondary data from six tertiary cancer hospitals in south India. DFS was calculated from the date of treatment completion to local or distant relapse, death, or last follow-up or date of censoring (31 December 2018) whichever was earlier. Adjusted hazard ratios (HRs) and 95% CIs were calculated using Cox regression analysis. Of 837 women, 288 (34.4%) had EBC and 549 (65.6%) had LABC. The mean age was 52.1 years (SD 10.4). Luminal A was the most frequent molecular subtype (36.7%) followed by triple-negative (25.4%), Her2/neu-enriched (14.9%) and luminal B Her2/neu-positive subtypes (13.1%). Three-year DFS was 92% among EBC and 76% among LABC. Among EBC group, molecular profile was not associated with DFS. On adjusted analysis among LABC group, when compared to luminal A, triple-negative [aHR 3.95 (95% CI 1.78, 7.88)] and Her2-enriched [aHR 2.6 (95% CI 1.21, 5.61)] were associated with relapse. Certain molecular subtypes predicted survival in LABC group. However, early diagnosis and treatment appear to nullify this effect on survival.